Average rating
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Star rating
Your vote was cast
Thank you for your feedback
Thank you for your feedback
Authors
De Rycker, ManuHorn, David
Aldridge, Bree
Amewu, Richard K
Barry, Clifton E
Buckner, Frederick S
Cook, Sarah
Ferguson, Michael A J
Gobeau, Nathalie
Herrmann, Jennifer
Herrling, Paul
Hope, William
Keiser, Jennifer
Lafuente-Monasterio, Maria Jose
Leeson, Paul D
Leroy, Didier
Manjunatha, Ujjini H
McCarthy, James
Miles, Timothy J
Mizrahi, Valerie
Moshynets, Olena
Niles, Jacquin
Overington, John P
Pottage, John
Rao, Srinivasa P S
Read, Kevin D
Ribeiro, Isabela
Silver, Lynn L
Southern, Jen
Spangenberg, Thomas
Sundar, Shyam
Taylor, Caitlin
Van Voorhis, Wes
White, Nicholas J
Wyllie, Susan
Wyatt, Paul G
Gilbert, Ian H
Issue Date
2019-12-06
Metadata
Show full item recordAbstract
In May 2019, the Wellcome Centre for Anti-Infectives Research (WCAIR) at the University of Dundee, UK, held an international conference with the aim of discussing some key questions around discovering new medicines for infectious diseases and a particular focus on diseases affecting Low and Middle Income Countries. There is an urgent need for new drugs to treat most infectious diseases. We were keen to see if there were lessons that we could learn across different disease areas and between the preclinical and clinical phases with the aim of exploring how we can improve and speed up the drug discovery, translational, and clinical development processes. We started with an introductory session on the current situation and then worked backward from clinical development to combination therapy, pharmacokinetic/pharmacodynamic (PK/PD) studies, drug discovery pathways, and new starting points and targets. This Viewpoint aims to capture some of the learnings.Citation
ACS Infect Dis. 2019 Dec 6. doi: 10.1021/acsinfecdis.9b00371.Affiliation
HIPS, Helmholtz-Institut für Pharmazeutische Forschung Saarland, Universitätscampus E8.1 66123 Saarbrücken, Germany.Publisher
American Society for ChemistryJournal
ACS Infectious DiseasesPubMed ID
31808676Type
ArticleLanguage
enISSN
2373-8227ae974a485f413a2113503eed53cd6c53
10.1021/acsinfecdis.9b00371
Scopus Count
The following license files are associated with this item:
- Creative Commons
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-ShareAlike 4.0 International
Related articles
- [Development of antituberculous drugs: current status and future prospects].
- Authors: Tomioka H, Namba K
- Issue date: 2006 Dec
- Social sciences research on infectious diseases of poverty: too little and too late?
- Authors: Azoh Barry J
- Issue date: 2014 Jun
- ESCAIDE 2015: an operational scientific conference on infectious diseases for professionals from Europe and beyond.
- Authors: Sabbatucci M, Jasir A
- Issue date: 2016
- Report calls for $2bn global fund to kickstart antibiotic development.
- Authors: Wise J
- Issue date: 2015 May 14
- Shortening the decade-long gap between adult and paediatric drug formulations: a new framework based on the HIV experience in low- and middle-income countries.
- Authors: Penazzato M, Lewis L, Watkins M, Prabhu V, Pascual F, Auton M, Kreft W, Morin S, Vicari M, Lee J, Jamieson D, Siberry GK
- Issue date: 2018 Feb